BCG-unresponsive nonmuscle invasive bladder cancer: developing drugs and biologics for treatment
- Series Title(s):
- Guidance for industry
United States. Department of Health and Human Services, issuing body.
United States. Food and Drug Administration, issuing body.
Center for Biologics Evaluation and Research (U.S.), issuing body.
Center for Drug Evaluation and Research (U.S.), issuing body.
- Silver Spring, MD : Center for Drug Evaluation and Research, February 2018
- Clinical Trials as Topic -- standards Drug Evaluation -- standards Urinary Bladder Neoplasms -- drug therapy Biological Products -- therapeutic use Chemistry, Pharmaceutical Mycobacterium bovis Research Design Humans United States United States. Department of Health and Human Services. United States. Food and Drug Administration.
- Guideline Technical Report
- The National Library of Medicine believes this item to be in the public domain. (More information)
- 1 online resource (1 PDF file (10 pages)).
- NLM Unique ID:
- 101733968 (See catalog record)